In preclinical models of breast cancer, PMN formation can be prevented by inhibition of P2RY2 signaling or modulation of LOX with β-aminopropionitrile (β-APN), function-blocking antibodies, or LOX-specific RNA interference. This evidence concerns the gene LOX and breast cancer.